Dina Ramadane
Stock Analyst at Bank of America Securities
(1.62)
# 3,471
Out of 5,028 analysts
28
Total ratings
33.3%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Buy | $66 | $36.82 | +79.25% | 11 | Sep 16, 2026 | |
| BHVN Biohaven | Reiterated: Sell | $11 | $16.95 | -35.10% | 10 | Aug 27, 2026 | |
| PROK ProKidney | Reiterated: Sell | $1 | $1.74 | -42.53% | 3 | Aug 10, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $32 → $45 | $43.89 | +2.53% | 2 | Aug 7, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 → $30 | $37.08 | -19.09% | 2 | Aug 7, 2026 |
Vera Therapeutics
Sep 16, 2026
Reiterated: Buy
Price Target: $66
Current: $36.82
Upside: +79.25%
Biohaven
Aug 27, 2026
Reiterated: Sell
Price Target: $11
Current: $16.95
Upside: -35.10%
ProKidney
Aug 10, 2026
Reiterated: Sell
Price Target: $1
Current: $1.74
Upside: -42.53%
Immunovant
Aug 7, 2026
Reiterated: Buy
Price Target: $32 → $45
Current: $43.89
Upside: +2.53%
Amylyx Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $22 → $30
Current: $37.08
Upside: -19.09%